| Regulatory
Matters |
| |
Botulinum
toxins Type A and Type B |
| |
Ceftriaxone |
| |
Chromic
Phosphate P32 |
| |
Cough
and cold medicines |
| |
Dietary
supplements |
| |
Erlotinib |
| |
Etanercept |
| |
Hydroxyzine
hydrochloride |
| |
Salicylate
containing oral gels |
| |
Testosterone
gel products |
| |
Trastuzumab |
|
Safety of Medicines |
| |
Aliskiren |
| |
Angiotensin
converting enzyme inhibitors and angiotensin II receptor antagonists |
| |
Antiepileptics |
| |
Antipsychotics |
| |
Atypical
antipsychotics |
| |
Bevacizumab |
| |
Cefaclor |
| |
Clopidogrel |
| |
Corticosteroids |
| |
Flecainide |
| |
Immunoglobulin |
| |
Isotretinoin |
| |
Lignocaine
with Clorhexidine |
| |
Methylthioninium
chloride |
| |
Non-steroidal
anti-inflammatory drugs |
| |
Phosphate
containing laxatives |
| |
Red
yeast rice extract |
| |
Selective
serotonin reuptake inhibitors |
| |
Sodium
valproate |
| |
Varenicline |
| Feature |
| |
Advisory
Committee on Safety of Medicinal Products (ACSoMP) |